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ABSTRACT
Background: Specialized multidisciplinary clinics have been shown to
reduce mortality in heart failure (HF). Our objective was to evaluate the
cost-effectiveness of this model of care delivery.
Methods: We performed a cost-effectiveness analysis, with a 12-year time
horizon, from the perspective of the Ontario Ministry of Health and
Long-term Care, comparing a standard care cohort, consisting of all
patients admitted to hospital with HF in 2005, to a hypothetical cohort
treated in HF clinics. Survival curves describing the natural history of HF
were constructed using mortality estimates from the Enhanced Feedback
for Effective Cardiac Treatment (EFFECT) study. Survival beneﬁts and
resource uptake associated with HF clinics were estimated from a meta-
analysis of published trials. HF clinics costs were obtained by costing a
representative clinic in Ontario. Health-related costs were determined
through linkage to administrative databases. Outcome measures included
life expectancy (years), costs (in 2008 Canadian dollars) and the incre-
mental cost-effectiveness ratio (ICER).
Results: HF clinics were associated with a 29% reduction in all-cause
mortality (risk ratio [RR] 0.71; 95% conﬁdence interval [CI] 0.56–0.91)
but a 12% increase in hospitalizations (RR 1.12; 95% CI 0.92–1.135).
The cost of care in HF clinics was $52 per 30 patient-days. Projected
life-expectancy of HF clinic patients was 3.91 years, compared to 3.21
years for standard care. The 12-year cumulative cost per patient in the HF
clinic group was $66,532 versus $53,638 in the standard care group. The
ICER was $18,259/life-year gained.
Conclusions: HF clinics appear to be a cost effective way of delivering
ambulatory care to HF patients.
Keywords: cost-effectiveness analysis, health policy and outcome research,
heart failure, multidisciplinary care.
Introduction
Heart failure (HF) is a complex, progressive syndrome character-
ized by abnormal heart function resulting in poor exercise toler-
ance, recurrent hospitalizations, and reductions in both quality of
life and survival [1]. Although tremendous progress has been
made in pharmacologic and device therapy, HF patients continue
to have a poor prognosis, with an annual mortality ranging from
5% to 50% [1]. The incidence of HF is projected to increase, with
estimates suggesting a threefold increase in HF hospitalizations
over the next decade [2]. Alternative targeted health care delivery
models have, therefore, been of particular interest in HF, as a
means of improving both quality of life and survival [3].
Disease management through specialized multidisciplinary
clinics has been shown to improve patient outcomes in several
health conditions, including asthma, diabetes mellitus, chronic
kidney disease, and cancer [4,5]. The potential beneﬁts of multi-
disciplinary care in HF clinics include the improved utilization
and compliance with evidence-based medications that prolong
survival. Moreover, this model of care may better address the
complex interplay between medical, psychosocial, and behav-
ioral factors facing HF patients and their caregivers [3]. Several
previous randomized studies and meta-analyses have evaluated
the efﬁcacy of such clinics, with selected results suggesting a
marked reduction in mortality [1,3,6]. However, interpreting this
literature is challenging because the composition of HF clinics
and the interventions they offer have varied, as has the popula-
tion studied [3].
From a health policy standpoint, it remains unclear if the
beneﬁt of HF clinics is balanced against the costs of the interven-
tion itself and the subsequent future health care costs associated
with more closely managed care. Previous economic evaluations
of HF clinics have been restricted to relatively small clinical trials,
most with short time horizons [3,7–11]. Accordingly, our objec-
tive was to determine the cost-effectiveness of specialized multi-
disciplinary HF clinics compared to standard care for the long
term management of HF patients in Ontario, Canada.
Methods
Research Ethics Board Approval
This study was approved by the Institutional Research Ethics
Board at Sunnybrook Health Sciences Centre, Toronto, Ontario.
Study Design
We performed a cost-effectiveness analysis to model the costs and
outcomes in a cohort of patients discharged after an index
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hospitalization for HF, comparing two treatment strategies: 1)
treatment in a specialized multidisciplinary HF clinic (deﬁned as
care involving at least one physician and nurse, one of whom has
specialized training in HF) versus, and 2) standard care (deﬁned
as care provided by a single practitioner). Outcomes of interest
were life expectancy, measured in years, costs (adjusted for inﬂa-
tion to 2008 Canadian dollars using the Bank of Canada Con-
sumer Price Index, http://www.bankofcanada.ca/en/cpi.html),
and the incremental cost-effectiveness ratio (ICER), calculated as
the incremental cost per life-year gained.
Economic Assumptions
The perspective of this analysis was that of the Ontario Ministry
of Health and Long-Term Care (MOHLTC), the single third-
party payer for health services in the province. The time horizon
for the analysis was 12 years, the period for which accurate
estimates of HF natural history in Ontario were available. All
health outcomes and costs were discounted at 5% per year
(http://www.cadth.ca).
Standard Care Cohort
The target population were patients with a recent hospitalization
for HF. For the purpose of estimating survival gain and cost, we
identiﬁed an actual cohort of all patients in the ﬁscal year 2005
that were discharged from hospital with a diagnosis of HF in
Ontario. Patients were identiﬁed based on International Classi-
ﬁcation of Disease (ICD) Version 10 code I50 in the Canadian
Health Institute for Health Information (CIHI) discharge
abstract database. We restricted the cohort to patients above the
age of 25 years who were residents of Ontario with valid Ontario
Health Insurance Plan (OHIP) identiﬁcation numbers. If an indi-
vidual had more than one HF hospitalization for 2005, the ﬁrst
admission was deﬁned as the index event. Based on this deﬁni-
tion, we identiﬁed 16,443 hospitalized HF patients who repre-
sented our standard care cohort.
HF Clinic Cohort
A hypothetical HF clinic cohort was modeled, using the same
16,443 patients identiﬁed earlier. Life expectancy and costs were
estimated in this modeled cohort as described below.
Estimation of Life Expectancy
We used age-gender speciﬁc mortality rates from the Enhanced
Feedback for Effective Cardiac Treatment (EFFECT) study to
estimate the life-expectancy of HF with standard care. The
EFFECT study was a chart abstraction of 9943 HF patients,
across 44 hospitals in Ontario followed for up to 12 years.
Patients in the EFFECT study were from a wide spectrum of
clinical settings, including both large tertiary care centers and
smaller rural community hospitals, and thus were representative
of HF in Ontario. Survival curves were constructed for patients
receiving standard care using the age-gender speciﬁc life-tables
from the EFFECT study [12].
Estimates for life expectancy of patients treated in HF clinics
were obtained from a systematic review and meta-analysis of the
literature, which is published separately [13]. To ensure that these
efﬁcacy estimateswere representative of the treatment strategies in
our model, the systematic review was restricted to randomized
controlled trials of HF clinics consisting, at a minimum, of a nurse
and physician, one of whom was a specialist in HF management
[13]. These trials compared HF clinics to standard care by a
single practitioner, and the population was restricted to HF
patients after discharge from hospital [13]. Summary risk ratio
(RR) estimates for mortality and hospitalization were calculated
using the random effects model of DerSimonian and Laird
(Table 1). The systematic review included eight randomized con-
trolled trials (found at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i8_Wijeysundera.asp) [14–21]. The
meta-analysis concluded that HF clinics are associated with a
statistically signiﬁcant 29% decrease in all-cause mortality
(summary RR 0.71; 95% conﬁdence interval [CI] 0.56–0.91) but
a nonsigniﬁcant 12% increase in overall hospitalizations
(summary RR 1.12; 95% CI 0.92–1.35) [13].
Survival curves for the HF clinic cohort were then constructed
by applying the summary estimate from the meta-analysis to the
natural history survival curves constructed from the EFFECT
study. Based on expert opinion, we incorporated a 10% annual
attrition rate of patients dropping out from the HF clinics into
our model. We assumed that the survival beneﬁt afforded by HF
clinics only applied to patients who continued to receive care in
these clinics. Patients who dropped out of HF clinic care were
assumed to have the same mortality rate as those patients receiv-
ing standard care. We also assumed that noncompliant patients
would not return to HF clinic care.
HF Clinic Costs
Incremental costs associated with treatment provided at HF
clinics were identiﬁed from an existing HF clinic at the University
Health Network (UHN) in Toronto, Ontario which we consid-
ered to be representative of specialized multidisciplinary HF
clinics in the province. Where selected costs could not be valued,
clinical experts were consulted. Brieﬂy, care at the UHNHF clinic
is primarily provided by a physician with speciﬁc training in HF
management and an advanced care nurse practitioner. Care is
also provided by allied health care professions as needed. On
average, patients had two clinic visits per year; new patients or
patients with unstable symptoms were evaluated more
frequently.
The types of costs that were considered for the HF clinic are
summarized in Table 2. These included costs associated with: 1)






RR for all-cause mortality 0.71 (0.56–0.91) Meta-analysis (13) Log-normal
RR for all-cause hospitalization 1.12 (0.92–1.35) Meta-analysis (13) Log-normal
RR for emergency visit 1 (0.5–1.5) Assumption Log-normal
RR for physician assessment/lab test 1.2 (0.7–1.7) Assumption Log-normal
RR for same day surgery 1 (0.5–1.5) Assumption Log-normal
RR for medication 1 (0.5–1.5) Assumption Log-normal
Annual attrition rate from heart failure clinics 0.1 (0–1) Assumption Beta
CI, conﬁdence interval; OR, odds ratio; PSA, probabilistic sensitivity analysis.
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health practitioner visits and clinic stafﬁng (including physician,
nurse practitioner, pharmacist, dietician, social worker, kinesi-
ologist, and clerical staff); 2) laboratory and imaging tests; and 3)
operating and overhead (plant operations, cleaning, waste dis-
posal and pest removal, ﬁre safety, security, building repairs and
maintenance, equipment depreciation, administrative fees, utili-
ties). Stafﬁng costs were estimated using a top-down approach
based on annual staff salaries including beneﬁts, adjusted by the
proportion of time spent in the HF clinic. For laboratory and
imaging test, we used a bottom-up approach, assuming that
patients would have an electrocardiogram (EKG) every visit, an
echocardiogram once a year, and annual screening blood-work
assessing renal function, electrolytes and hematologic proﬁle. We
used these assumptions to estimate an average cost per 30-day
period, which we assumed was constant over the model’s time
horizon.
Costs Associated with Standard Care
Health-related costs for the standard care cohort were deter-
mined using a bottom-up approach by linkage to population-
based administrative databases at the Institute for Clinical
Evaluative Sciences (ICES), using encrypted unique patient iden-
tiﬁers [22]. Administrative records were available up to March
31t, 2008, allowing cost-estimates for a maximum follow-up
period of 36 months. We identiﬁed all health-related resources
utilized by patients within the study period and paid for by the
Ontario MOHLTC. The categories of costs included were all-
cause physician visits, acute care and chronic care hospitaliza-
tions, emergency department visits, and same day surgeries. We
included only costs associated with HF related medication use.
Costs associated with physician visits and laboratory tests
were determined using data from the claims history in OHIP
database, which includes fee-for-service claims submitted by phy-
sicians and other licensed health professionals]. It also includes
shadow billings from providers of organizations covered by alter-
nate payment arrangements. Because there are regional varia-
tions in reimbursements, the median 2008 cost for each physician
and laboratory service fee code was used to estimate cost.
The CIHI discharge abstract database has records on the
frequency and type of all acute and chronic care hospitalizations
in the patients included in our cohort. The CIHI discharge record
includes a “most responsible” diagnosis and up to 15 additional
diagnosis codes that can be used to estimate comorbidity, as well
as procedure codes, length of stay and in-hospital mortality data
[22]. The cost of hospitalization was estimated using the
Resource Intensity Weight (RIW) methodology [22]. We multi-
plied the RIW associated with the case-mix group for each hos-
pitalization by the average provincial cost per weighted case for
all Ontario acute and chronic hospitals [22]. This method yields
a mean cost per hospitalization for cases assigned to a particular
case-mix group category.
A similar RIW methodology was employed to determine the
costs for emergency department visits and same day surgeries,
both using the National Ambulatory Care Reporting Service
(NACRS) database [22]. NACRS contains administrative, clini-
cal, ﬁnancial, and demographic data for hospital-based ambula-
tory care, including emergency department visits, outpatient
surgical procedures, medical day/night care, and high-cost ambu-
latory clinics such as dialysis, cardiac catheterization, and oncol-
ogy [22].
Finally, data on medication costs were obtained from the
Ontario Drug Database (ODB), which has comprehensive drug
utilization information on patients more than 65 years, for
whom full drug coverage is provided for by the MOHLTC [22].
We did not include medication costs associated with patients
under the age of 65 years as these would not be covered by the
provincial government. We restricted our analysis to HF medi-
cations because we did not anticipate that HF clinics would have
any impact on non-HF medication use. HF medication classes
included angiotension converting enzyme (ACE) inhibitors,
angiotension receptor blockers (ARB), beta-blockers, digoxin,
spironolactone, diuretics (furosemide, metolazone), hydralazine,
and long-acting nitrates.
Health care costs associated with the treatment of these HF
patients required modeling, because our follow-up period for
observed linked costs was limited to 36 months and, therefore,
did not span the 12-year time horizon of the analysis. Based on
results of previous studies in cancer care, we expected that
health-related costs would not be constant over the lifetime of
HF patients [23]. Instead, we expected that there would be a
phase of high costs associated with the time period immediately
after hospital discharge, followed by a phase of clinical stability
characterized by relatively constant costs, and ﬁnally a phase of
increasing costs before death [23]. To validate our phased-based
costing approach and determine the duration of the postdis-
charge and predeath phases of increased costs, we performed
exploratory analyses of our linked cohort.
We evaluated the cost per consecutive 30-patient days for
patient subgroups that survived 9 to 12 months, 21 to 24
months, and 33 to 36 months postdischarge (Fig. 1). As seen in
Figure 1, the mean 30 patient-day costs curves conﬁrmed our
hypothesis of discrete cost phases. Inﬂection points separating
the postdischarge and stable phases, and the stable and predeath
phases were estimated to occur at 3 months postdischarge, and 6
months before death, respectively. Thirty patient-day blocks of
consecutive costs were created within each costing phase, with
three blocks for the postdischarge phase, six blocks for the pre-
death phase, and a single 30 patient-day block of consecutive
costs for the stable phase (see Table 3).
We then assigned individual patient costs to each 30-day
costing block within the three phases in a hierarchical fashion,
ﬁrst to the postdischarge phase, then to the predeath phase, and
ﬁnally to the stable phase. For example, if a patient survived for
12 months postdischarge, the mean cost for each of the ﬁrst 3
months were assigned to each of the corresponding three 30






Cardiac Technician† 38,311 2.86
Physician† 176,735 13.20
Clerical (booking)† 58,523 4.37
Clerical (charting, data entry)† 17,136 1.28
Dietician† 4,539 0.34
Kinesiologist† 13,322 1.00
Nurse practitioner† 42,822 3.20
Pharmacist† 9,326 0.70
Social worker† 2,731 0.20
Operating costs 6,178 0.46
Utility charge 2,265 0.17
Blood Work 35,255 2.63
Electrocardiogram‡ 32,455 2.42
Echocardiogram‡ 255,860 19.11
Cost per 30 patient-days 52
*Cost per 30 patient-day block was calculated by dividing the 1 year total costs by the total
number of patient visits in the clinic for 1 year, and multiplied by (30/365 days) to determine
the cost per 30 patient-days.
†1 year cost calculated by product of yearly salary (including beneﬁts) by average proportion
of time spent in HF clinic.
‡Patients assumed to have one echocardiogram per year, and one electrocardiogram (EKG)
per visit.
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patient-day blocks of consecutive costs of the postdischarge
phase; the mean cost for each of the last 6 months of life were
assigned to each of the corresponding six costing blocks in the
predeath phase; ﬁnally, the remaining 3 months were assigned to
the stable category.
Costs for each of the 16,443 patients in our standard care
cohort were assigned in this manner. Table 3 summarizes the
mean cost for each of the 30 patient-day blocks of consecutive
costs. The cumulative lifetime costs for the standard care cohort
were estimated by ﬁrst determining the proportion of the original
cohort in each costing block for each 30-day time point in the
model over its 12-year time horizon. The total costs at each
30-day time point was then calculated by multiplying the mean
cost per block (in Table 3), by the number of patients in the
costing block. The cumulative costs were the sum of the costs
across all the time blocks.
Tomodel the lifetime costs for theHF clinic group,we adjusted
the standard care cost per 30 patient-day block of consecutive
costs using estimates from our systematic review (Table 1) and
added this to the incremental intervention costs associated with
HF clinics, as described earlier. For example, we found that
all-cause hospitalization increased by 12% (Table 3). Therefore,
the acute care hospitalization component of the mean 30 patient-
day cost for standard care in each of the costing blocks in Table 2
was increased by 12%. Only a minority of the studies in the
systematic review provided data on medication utilization. These
suggested that althoughHF clinic patients had dose intensiﬁcation
compared to those in standard care, the number of medication
classes prescribed was not statistically different. We assumed
medication costs to be similar between treatment strategies and
tested this in our sensitivity analyses. We expected that care in a
specialized HF clinic would result in a greater number of subse-
quent cardiac investigations, such as cardiac magnetic resonance
imaging or coronary angiography; based on expert opinion, we
assumed a 20% increase in diagnostic testing in the HF clinic
strategy. The modeled costs per 30 patient-days for each of the
costing blocks for the HF groups are summarized in Table 3.
Sensitivity Analyses
One-way deterministic sensitivity analyses were performed to
evaluate the robustness of our results. The ranges for the sensi-
tivity analysis were obtained from the 95% conﬁdence intervals
from the source documentation (Table 3). We also performed a
probabilistic sensitivity analysis (PSA), using second-order
Monte Carlo simulation with 10,000 trials. Beta distributions
were used to deﬁne all probabilities, and log-normal distributions
were used to deﬁne costs and ORs; mean and standard deviations
Figure 1 Exporatory analysis on phases of long
term cost associated with HF care.
Table 3 Long-term costs (all costs are reported in 2008 Canadian dollars)
30-day block
Observed costs (standard care)
Modeled costs
(HF clinics)
Physician Services Hospitalization ER Same day surgery Medications Overall costs Overall costs
Postdischarge phase
1 block postdischarge 1,170 8,725 617 103 59 10,675 11,955
2 block postdischarge 462 2,267 129 47 56 2,961 3,326
3 block postdischarge 373 1,599 105 42 52 2,172 2,438
Stable phase
Stable phase 144 384 36 23 31 617 692
Predeath phase
6 block predeath 437 2,344 178 37 66 3,062 3,430
5 block predeath 480 2,721 195 37 67 3,501 3,923
4 block predeath 530 3,241 211 30 65 4,077 4,571
3 block predeath 608 4,162 251 34 63 5,119 5,740
2 block predeath 872 7,389 356 41 57 8,716 9,777
1 block predeath 842 7,020 405 20 21 8,308 9,318
ER, emergency room; HF, heart failure.
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to deﬁne distributions were obtained from source documenta-
tion. Where standard deviations were not available, we assumed
a standard deviation that was 50% of the mean. A cost-
effectiveness acceptability curve was produced at varying
willingness-to-pay thresholds by drawing parameter values at
random from all distributions.
The cost-effectiveness analysis model was conducted in
Microsoft Excel Version 2007 (Microsoft Cooperation,
Redmond, WA), and the PSA was conducted using Oracle
Crystal Ball Version 11.1.1 (Oracle Corporation, Redwood, CA).
Long term health related costs were estimated using SAS Version
9.1 (SAS Institute Inc, Cary, NC).
Results
The characteristic of the 16,443 patients in our cohort are sum-
marized in Table 4. The mean age of the cohort was 76.8 years,
with 49.4% being male. A total of 39.8% of patients had an
ischemic cardiomyopathy, while 45.9% had diabetes, 84.7% had
hypertension and 17.2% had renal insufﬁciency.
The estimated cost of treatment at a multidisciplinary HF
clinic was estimated to be $52 per 30 patient-days, or $624 per
patient per year. The individual components of care are summa-
rized in Table 2. The major contributors to the overall cost of
care were the physician assessment fee (25.4%) and diagnostic
tests performed in the clinic (46.5%), most notably echocardio-
graphy (36.8%). Costs associated with nurse practitioner care
were only 6.2% of total costs, while those associated with other
staff represented nearly 21% of clinic costs.
The mean cost per 30 patient day costing block for long-term
costs are presented in Table 3. Within both the postdischarge and
predeath phases, there were substantial differences in mean cost
between costing blocks. For example, the mean cost was $10,675
in the ﬁrst 30 days after discharge, followed by a 75% reduction
to $2961 for the second month postdischarge. Similarly, in the 6
months before death, there was a steep increase from $3062 in
the ﬁrst predeath costing block, to $8308 immediately before
death. The largest contributor to overall health-related future
costs was hospitalizations for all the costing blocks. Hospitaliza-
tion costs were most prominent during the more acute phases of
the diseases (i.e., the postdischarge and predeath phases), when
they represented more than 80% of total costs. In contrast, in the
stable phase hospitalizations represented only approximately
50% of costs, during which time costs associated with medica-
tions (5%) and physician services (15%) played a larger role.
At 12 years, nearly all of the patients in either cohort were
projected to have died (94.6% in the standard care group versus
92.1% in the HF clinic group). However, death was delayed in
the HF clinic cohort. The life expectancy of HF patients treated
with standard care was estimated to be 3.21 years. In compari-
son, as seen in Figure 2, those treated at HF clinics were esti-
mated to have an average survival of 3.91 years, a survival gain
of approximately 8.5 months. The cumulative lifetime cost asso-
ciated with standard care was $53,638 compared to $66,532 for
patients in the HF clinic group. Thus, HF clinics cost $18,259 for
each additional life-year gained (ICER is $17,427 for costs and
health effects not discounted) (Table 5).
Deterministic (one-way) sensitivity analyses demonstrate that
these results were robust, across the range of plausible values.
Speciﬁcally we did not ﬁnd that our results varied if medication
and diagnostic tests costs associated with specialized HF clinics
increased by 50%. Importantly, if the mortality beneﬁt associated
with HF clinics was assumed to be the limits of the 95% conﬁ-
dence interval from the systematic review (RR 0.56–0.91), the
HF clinic strategy remained cost-effective. In addition, HF clinics
remained cost-effective if the proportion of patients who dropped
out annually was varied from 1% to 90%. Of 10,000 simula-
tions of the PSA, 99.4% were cost-effective at a willingness to a
pay threshold of $50,000, as seen in the cost-effectiveness accept-
ability curve displayed in Figure 3.
Table 4 Baseline characteristics of cohort of patients with heart failure
N = 16,443 (%)
Mean Age (years) 95% CI 76.8 (76.6–77.0)
% under age 65 95% CI 14.9 (14.4–15.6)
Male 95% CI 49.4 (48.4–50.5)
Coronary artery disease 95% CI 39.8 (38.9–40.8)
Old myocardial infarction 95% CI 31.5 (30.7–32.4)
Diabetes mellitus 95% CI 45.9 (44.9–47.0
Hypertension 95% CI 84.7 (83.3–86.1)
Cerebrovascular disease 95% CI 8.1 (7.7–8.5)
Renal insufﬁciency 95% CI 17.2 (16.6–17.9)
Pulmonary disease 95% CI 18.0 (17.4–18.7)
Dementia 95% CI 4.7 (4.3–5.0)
Malignancy 95% CI 6.7 (4.3–5.0)
CI, conﬁdence interval.
Figure 2 Survival curves for patients treated in health failure clinic versus
standard care.
Table 5 Life expectancy, cumulative costs and incremental cost-






Standard care $61,870 3.87
Heart failure clinic $77,882 4.78
D $16,012 0.92
ICER $17,427





Standard care $53,638 3.21
Heart failure clinic $66,532 3.91
D $12,895 0.71
ICER $18,259
HF, heart failure; ICER, incremental cost-effectiveness ratio; D, difference.
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Discussion
We performed a cost-effectiveness analysis from the perspective
of the MOHTLC of Ontario comparing multidisciplinary HF
clinics to standard care for patients discharged after a hospital-
ization for HF. We found that HF clinics were associated with an
improvement in estimated life expectancy of approximately 8.5
months over the 12-year time horizon of our model, a substantial
increase given the poor prognosis associated with this condition.
This survival beneﬁt balanced against the increased costs associ-
ated with the implementation of the multidisciplinary clinic itself
and a small increase in future hospitalizations. In contrast to
previous economic evaluations of HF clinics, our study examined
a large, real-world cohort over a long time horizon [3,7–11].
Moreover, ours is the ﬁrst study in the literature to use accurate
administrative datasets to estimate long term health related costs
[3,7–11]. These results were robust across a wide plausible range
of parameters, and alternative assumptions regarding costs and
beneﬁts of HF clinics, thereby providing evidence to suggest that
specialized multidisciplinary clinics are a cost-effective means of
providing ambulatory care to HF patients.
The prognosis for patients with HF has improved over the
last two decades with the introduction of neurohormonal modu-
lating therapies such as angiotensin-converting enzyme (ACE)
inhibitors, b-blockers, and aldosterone inhibitors as the mainstay
of pharmacological therapy for this complex condition. In the
past 5 years, improvements in device therapy with the use of
automated implantable cardiovertor deﬁbrillators (AICD) for the
prevention of arrhythmic deaths and resynchronization therapy
in suitable candidates has further reduced mortality. Nonetheless,
despite the availability of these therapies uptake remains poor in
part because the optimal use of these treatments requires close
supervision by appropriately trained personnel. The majority of
HF patients in Canada are treated by primary care physicians,
who may lack the expertise or time to optimize their patients’
medications or identify suitable candidates for advanced device
therapy [24].
Multidisciplinary clinics likely improve disease management
through a number of mechanisms. Given the focus on one par-
ticular disease and enhanced ability for close monitoring,
patients at a HF clinic may be more likely to receive appropriate
medications and, more importantly, receiving optimal doses
[1,6]. Dose intensiﬁcation to the levels used in clinical trials is
critical in order for patients to realize the maximum beneﬁt of
these medications. Such dose intensiﬁcation is facilitated by the
specialized supervision available at HF clinics. Furthermore,
these complex patients often have concomitant medical, behav-
ioral and social challenges, all of which need to be addressed
[1,6]. As such, the availability of allied health professions such as
pharmacists, dieticians, social workers and exercise therapist
likely contribute to the survival beneﬁt associated with HF
clinics.
Current American and Canadian practice guidelines suggest
as a Type 1 recommendation that certain subsets of HF patients,
speciﬁcally those recently admitted to hospital for a HF exacer-
bation, should be referred to a specialized HF clinic [1,6]. Our
study reinforces this recommendation by suggesting that this
beneﬁt was cost-effective compared to the traditional willingness
to pay threshold of $50,000. This cost-effectiveness persisted
despite an apparent increase in long-term hospitalizations and
their associated costs.
Our study has important implications for HF care. Given the
current climate of limited health care resources, it is essential that
any new treatment strategy demonstrate a favorable incremental
cost for its additional health beneﬁt. We found that HF clinics
had an ICER of approximately $18,000 per life-year gained,
which compares favorably to other recently adopted cardiac
technologies, such as drug eluting stents (ICER > $27,000 per
quality-adjusted life-year gained) [25–27]. As our perspective
was that of the third party payer (MOHLTC), we did not incor-
porate costs, such as caregiver expenses or productivity costs.
Given the mortality beneﬁt of HF clinics, and the evidence that
disease management strategies improve functional status, we
expect that a greater proportion of patients treated at HF clinics
would be able to return to work. However, as the majority of our
cohort was more than 65 years (85%), we anticipate that pro-
ductivity gains would be minimal in our cohort, and as such, our
estimates are comparable to those had we taken a societal
perspective.
This study must be interpreted within the context of several
important limitations. First, our estimates for the beneﬁts of HF
clinics are based on efﬁcacy values from randomized controlled
trials with restrictive enrolment criteria and therefore highly
selected populations. These are not necessarily generalizable to
real world effectiveness in unselected populations. Second, our
estimates for the impact of HF clinics are limited to changes in
mortality and hospitalizations. We assumed that HF clinics
would results in a greater use of subsequent tests and likely
medication use, but did not have any data upon which to base
our estimates. However, because our results were robust in the
sensitivity analyses to a wide range of plausible values for the
relative effect of HF clinics on these parameters, we do not
expect that our overall conclusions would change signiﬁcantly.
An additional limitation is that the costs for the HF clinic inter-
vention were estimated from a single HF clinic in Ontario.
However, we believe that this clinic is representative of the
HF clinics studied in the included trials in our meta-analysis (as
seen in Appendix A at:http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i8_Wijeysundera.asp), given its multi-
disciplinary approach and access to a range of allied health
professionals. Moreover, as a pretransplant clinic, it may in fact
include additional costs that will not be available in community
clinics. As such, we believe it provides a very conservative esti-
mation of the cost of this intervention. Finally, our model did
not account for any quality of life differences between treat-
ments as we restricted our outcomes to life-years and did not
incorporate utility weights. With more closely managed care, we
would anticipate that there would be greater identiﬁcation of
symptomatic deterioration and subsequent titration of diuretics
for example, to improve symptoms and, therefore, overall
quality of life. Therefore, we would expect that incorporating
quality of life weights would in fact amplify the differences we
observed between HF clinics and standard care.
Figure 3 Cost-effectiveness acceptability curve.
920 Wijeysundera et al.
In conclusion, in our cohort model examining the cost-
effectiveness of multidisciplinary HF clinics for posthospitalized
patients, we found that these clinics are a cost-effective interven-
tion with substantial mortality beneﬁts. Our results reinforce
guideline recommendations that these complex patients be
treated at such clinics.
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